Regeneron Pharmaceuticals Inc (REGN)

627.55
-6.45(-1.02%)
  • Volume:
    274,260
  • Bid/Ask:
    626.94/628.49
  • Day's Range:
    623.35 - 639.78

REGN Overview

Prev. Close
634
Day's Range
623.35-639.78
Revenue
13.54B
Open
637.77
52 wk Range
441.3-686.62
EPS
62.64
Volume
274,260
Market Cap
65.75B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
752,913
P/E Ratio
10.12
Beta
0.18
1-Year Change
25.51%
Shares Outstanding
104,555,539
Next Earnings Date
10 Feb 2022
What is your sentiment on Regeneron Pharmaceuticals Inc?
or
Vote to see community's results!

Regeneron Pharmaceuticals Inc Company Profile

Employees
9766

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellNeutralBuy
Technical IndicatorsStrong SellSellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellSellStrong Buy
  • this is the worst stock I had ever invested in. it just keeps going down and down with no bottom in sight. what a disgrace.
    3
    • Me too
      0
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.